drugset / Trial / NCT05286957
MRD-guided Adjuvant Tislelizumab and Chemotherapy in Resected Stage IIA-IIIB NSCLC
Phase 2
Recruiting
60 enrolled
The First Affiliated Hospital of Zhengzhou University
BeiGene · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Seagull is a phase Ⅱ study designed to investigate the efficacy and safety of MRD-guided adjuvant tislelizumab and chemotherapy vs adjuvant tislelizumab and chemotherapy in patients with resectable NSCLC
Timeline
- Start
- 2022-06-20
- Primary completion
- 2026-06-01
- Completion
- 2027-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | — | — |
| Subject | Cisplatin | Other / unclassified | — | — |
| Subject | Paclitaxel | Small molecule | — | — |
| Subject | Pemetrexed | Small molecule | — | — |
| Subject | Tislelizumab | Monoclonal antibody | 200 mg | — |